To allow, on a compassionate use basis, zalcitabine (ddC) for pediatric patients with
symptomatic HIV disease who have failed treatment or who are intolerant to zidovudine (AZT),
or who have completed other ddC protocols, or who are ineligible for ongoing clinical
Patients receive ddC and are evaluated at study entry and every 3 months thereafter, until 3
months after ddC becomes approved for pediatric patients or the sponsor deems it necessary
to terminate the protocol.
Patients must have:
- Symptomatic HIV infection.
- Failure on or intolerance to AZT monotherapy OR completed other ddC protocols OR been
ineligible for other ongoing clinical trials.
- Consent of parent or guardian required.
- Patients who do not meet the eligibility requirements may discuss their cases with
the medical monitor.